Compounds > noberastine
Page last updated: 2024-12-06

noberastine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID60531
CHEMBL ID2104704
SCHEMBL ID18424
MeSH IDM0189882

Synonyms (33)

Synonym
110588-56-2
D05196
noberastine (usan/inn)
noberastine
3-[(5-methylfuran-2-yl)methyl]-n-piperidin-4-ylimidazo[4,5-b]pyridin-2-amine
3-[(5-methyl-2-furanyl)methyl]-n-(4-piperidinyl)-3h-imidazo[4,5-b]pyridin-2-amine
VNIOQSAWKLOGLY-UHFFFAOYSA-N
3-(5-methylfurfuryl)-2-(4-piperidylamino)-3h-imidazo[4,5-b]pyridine
unii-wayb7mw5r0
3h-imidazo(4,5-b)pyridin-2-amine, 3-((5-methyl-2-furanyl)methyl)-n-4-piperidinyl-, (2z)-2-butenedioate (1:2)
wayb7mw5r0 ,
noberastine maleate
111922-05-5
r-64947
CHEMBL2104704
noberastina
3h-imidazo(4,5-b)pyridin-2-amine, 3-((5-methyl-2-furanyl)methyl)-n-4-piperidinyl-
unii-9hpd98ouwn
9hpd98ouwn ,
3-(5-methylfurfuryl)-2-(4-piperidylamino)-3h-imidazo(4,5-b)pyridine
r 64947
noberastina [inn-spanish]
noberastinum
noberastine [usan:inn:ban]
noberastinum [inn-latin]
noberastine [inn]
noberastine [usan]
noberastine [mart.]
SCHEMBL18424
DTXSID50149317
3-((5-methylfuran-2-yl)methyl)-n-(piperidin-4-yl)-3h-imidazo[4,5-b]pyridin-2-amine
Q27272574
AKOS040747215

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Incidence and severity of adverse experiences of NOB-treated groups were comparable in incidence and severity to placebo treatment."( Clinical evaluation of the efficacy and safety of noberastine, a new H1 antagonist, in seasonal allergic rhinitis: a placebo-controlled, dose-response study.
Alexander, M; Arnott, WS; Del Carpio, J; Drouin, MA; Knight, A; Yang, WH, 1991)		0.53
"We studied H1 antihistaminic safety, with respect to CNS, and clinical trial validity to determine its adverse effects and generalize the results."( [Data on the safety of antihistaminics obtained from published clinical trials].
González, JL; Rodríguez Paredes, A, )		0.13
" Patients that use modern antihistaminics have less adverse effects (32."( [Data on the safety of antihistaminics obtained from published clinical trials].
González, JL; Rodríguez Paredes, A, )		0.13
"Second generation antihistaminics have less adverse effects and similar efficacy than classics ones."( [Data on the safety of antihistaminics obtained from published clinical trials].
González, JL; Rodríguez Paredes, A, )		0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (4)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's4 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.37

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.37 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.37)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (40.00%)5.53%
Reviews1 (20.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other2 (40.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
histamine
[no description available]		3.7721aralkylamino compound;
imidazoles		human metabolite;
mouse metabolite;
neurotransmitter
azelastine
azelastine: azeptin is azelastine hydrochloride; structure; eye drop formulation effective in relieving symptoms of allergic conjunctivitis; do not confuse with 5-loxin which is an extract of Boswellia. azelastine : A phthalazine compound having an oxo substituent at the 1-position, a 1-methylazepan-4-yl group at the 2-position and a 4-chlorobenzyl substituent at the 4-position.		6.9810monochlorobenzenes;
phthalazines;
tertiary amino compound		anti-allergic agent;
anti-asthmatic drug;
bronchodilator agent;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
H1-receptor antagonist;
platelet aggregation inhibitor
cetirizine
Cetirizine: A potent second-generation histamine H1 antagonist that is effective in the treatment of allergic rhinitis, chronic urticaria, and pollen-induced asthma. Unlike many traditional antihistamines, it does not cause drowsiness or anticholinergic side effects.. cetirizine : A member of the class of piperazines that is piperazine in which the hydrogens attached to nitrogen are replaced by a (4-chlorophenyl)(phenyl)methyl and a 2-(carboxymethoxy)ethyl group respectively.		6.9810ether;
monocarboxylic acid;
monochlorobenzenes;
piperazines		anti-allergic agent;
environmental contaminant;
H1-receptor antagonist;
xenobiotic
triprolidine
Triprolidine: Histamine H1 antagonist used in allergic rhinitis; ASTHMA; and URTICARIA. It is a component of COUGH and COLD medicines. It may cause drowsiness.. triprolidine : An N-alkylpyrrolidine that is acrivastine in which the pyridine ring is lacking the propenoic acid substituent. It is a sedating antihistamine that is used (generally as the monohydrochloride monohydrate) for the relief of the symptoms of uticaria, rhinitis, and various pruritic skin disorders.		1.9810N-alkylpyrrolidine;
olefinic compound;
pyridines		H1-receptor antagonist
acrivastine
acrivastine: a second generation antihistamine. acrivastine : A member of the class of pyridines that is (pyridin-2-yl)acrylic acid substituted at position 6 by a [(1E)-1-(4-methylphenyl)-3-(pyrrolidin-1-yl)prop-1-en-1-yl group. It is a non-sedating antihistamine used for treatment of hayfever, urticaria, and rhinitis.		6.9810alpha,beta-unsaturated monocarboxylic acid;
N-alkylpyrrolidine;
olefinic compound;
pyridines		H1-receptor antagonist
ConditionIndicatedRelationship StrengthStudiesTrials
Atopic Hypersensitivity
[description not available]		03.3711
Itching
[description not available]		03.3711
Pruritus
An intense itching sensation that produces the urge to rub or scratch the skin to obtain relief.		03.3711
Hay Fever
[description not available]		03.3611
Rhinitis, Allergic, Seasonal
Allergic rhinitis that occurs at the same time every year. It is characterized by acute CONJUNCTIVITIS with lacrimation and ITCHING, and regarded as an allergic condition triggered by specific ALLERGENS.		03.3611